354 related articles for article (PubMed ID: 28081709)
1. Calprotectin (S100A8/A9) has the strongest association with ultrasound-detected synovitis and predicts response to biologic treatment: results from a longitudinal study of patients with established rheumatoid arthritis.
Nordal HH; Brokstad KA; Solheim M; Halse AK; Kvien TK; Hammer HB
Arthritis Res Ther; 2017 Jan; 19(1):3. PubMed ID: 28081709
[TBL] [Abstract][Full Text] [Related]
2. Calprotectin (S100A8/A9) and S100A12 are associated with measures of disease activity in a longitudinal study of patients with rheumatoid arthritis treated with infliximab.
Nordal HH; Brun JG; Hordvik M; Eidsheim M; Jonsson R; Halse AK
Scand J Rheumatol; 2016 Jul; 45(4):274-81. PubMed ID: 26767827
[TBL] [Abstract][Full Text] [Related]
3. Serum calprotectin (S100A8/9): an independent predictor of ultrasound synovitis in patients with rheumatoid arthritis.
Hurnakova J; Zavada J; Hanova P; Hulejova H; Klein M; Mann H; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Komarc M; Vencovsky J; Pavelka K; Senolt L
Arthritis Res Ther; 2015 Sep; 17(1):252. PubMed ID: 26373925
[TBL] [Abstract][Full Text] [Related]
4. The soluble biomarker calprotectin (an S100 protein) is associated to ultrasonographic synovitis scores and is sensitive to change in patients with rheumatoid arthritis treated with adalimumab.
Hammer HB; Fagerhol MK; Wien TN; Kvien TK
Arthritis Res Ther; 2011; 13(5):R178. PubMed ID: 22029973
[TBL] [Abstract][Full Text] [Related]
5. Calprotectin and TNF trough serum levels identify power Doppler ultrasound synovitis in rheumatoid arthritis and psoriatic arthritis patients in remission or with low disease activity.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2016 Jul; 18(1):160. PubMed ID: 27391315
[TBL] [Abstract][Full Text] [Related]
6. The neutrophil protein S100A12 is associated with a comprehensive ultrasonographic synovitis score in a longitudinal study of patients with rheumatoid arthritis treated with adalimumab.
Nordal HH; Brun JG; Halse AK; Jonsson R; Fagerhol MK; Hammer HB
BMC Musculoskelet Disord; 2014 Oct; 15():335. PubMed ID: 25282581
[TBL] [Abstract][Full Text] [Related]
7. Calprotectin (S100A8/A9) should preferably be measured in EDTA-plasma; results from a longitudinal study of patients with rheumatoid arthritis.
Nordal HH; Fagerhol MK; Halse AK; Hammer HB
Scand J Clin Lab Invest; 2018; 78(1-2):102-108. PubMed ID: 29278951
[TBL] [Abstract][Full Text] [Related]
8. Clinical and sonographic biomarkers of structural damage progression in RA patients in clinical remission: A prospective study with 12 months follow-up.
Ramírez J; Narváez JA; Ruiz-Esquide V; Hernández-Gañán J; Cuervo A; Inciarte-Mundo J; Hernández MV; Sampayo-Cordero M; Pablos JL; Sanmartí R; Cañete JD
Semin Arthritis Rheum; 2017 Dec; 47(3):303-309. PubMed ID: 28549731
[TBL] [Abstract][Full Text] [Related]
9. Serum calprotectin as a marker of ultrasound-detected synovitis in early psoriatic and rheumatoid arthritis: results from a cross-sectional retrospective study.
Sakellariou G; Lombardi G; Vitolo B; Gomarasca M; Faraldi M; Caporali R; Banfi G; Montecucco C
Clin Exp Rheumatol; 2019; 37(3):429-436. PubMed ID: 30299248
[TBL] [Abstract][Full Text] [Related]
10. Calprotectin as a marker of inflammation in patients with early rheumatoid arthritis.
Jonsson MK; Sundlisæter NP; Nordal HH; Hammer HB; Aga AB; Olsen IC; Brokstad KA; van der Heijde D; Kvien TK; Fevang BS; Lillegraven S; Haavardsholm EA
Ann Rheum Dis; 2017 Dec; 76(12):2031-2037. PubMed ID: 28814431
[TBL] [Abstract][Full Text] [Related]
11. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
[TBL] [Abstract][Full Text] [Related]
12. Ultrasound of the hand is sufficient to detect subclinical inflammation in rheumatoid arthritis remission: a post hoc longitudinal study.
Hammer HB; Kvien TK; Terslev L
Arthritis Res Ther; 2017 Oct; 19(1):221. PubMed ID: 28978340
[TBL] [Abstract][Full Text] [Related]
13. Ultrasound-detected bone erosion is a relapse risk factor after discontinuation of biologic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis whose ultrasound power Doppler synovitis activity and clinical disease activity are well controlled.
Kawashiri SY; Fujikawa K; Nishino A; Okada A; Aramaki T; Shimizu T; Umeda M; Fukui S; Suzuki T; Koga T; Iwamoto N; Ichinose K; Tamai M; Mizokami A; Nakamura H; Origuchi T; Ueki Y; Aoyagi K; Maeda T; Kawakami A
Arthritis Res Ther; 2017 May; 19(1):108. PubMed ID: 28545509
[TBL] [Abstract][Full Text] [Related]
14. Circulating calprotectin (S100A8/A9) is higher in rheumatoid arthritis patients that relapse within 12 months of tapering anti-rheumatic drugs.
de Moel EC; Rech J; Mahler M; Roth J; Vogl T; Schouffoer A; Goekoop RJ; Huizinga TWJ; Allaart CF; Toes REM; Schett G; van der Woude D
Arthritis Res Ther; 2019 Dec; 21(1):268. PubMed ID: 31805992
[TBL] [Abstract][Full Text] [Related]
15. Serum levels of CXCL13 are associated with ultrasonographic synovitis and predict power Doppler persistence in early rheumatoid arthritis treated with non-biological disease-modifying anti-rheumatic drugs.
Bugatti S; Manzo A; Benaglio F; Klersy C; Vitolo B; Todoerti M; Sakellariou G; Montecucco C; Caporali R
Arthritis Res Ther; 2012 Feb; 14(1):R34. PubMed ID: 22336440
[TBL] [Abstract][Full Text] [Related]
16. Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study.
Hurnakova J; Hulejova H; Zavada J; Hanova P; Komarc M; Mann H; Klein M; Sleglova O; Olejarova M; Forejtova S; Ruzickova O; Vencovsky J; Pavelka K; Senolt L
PLoS One; 2017; 12(8):e0183420. PubMed ID: 28832684
[TBL] [Abstract][Full Text] [Related]
17. Relation of Doppler ultrasound synovitis versus clinical synovitis with changes in native complement component levels in rheumatoid arthritis patients treated with biologic disease-modifying anti-rheumatic drugs.
Montoro Alvarez M; Chong OY; Janta I; González C; López-Longo J; Monteagudo I; Valor L; Garrido J; Lau IS; Rosman A; Naredo E; Carreño L
Clin Exp Rheumatol; 2015; 33(2):141-5. PubMed ID: 25665178
[TBL] [Abstract][Full Text] [Related]
18. Serum Calprotectin Versus Acute-Phase Reactants in the Discrimination of Inflammatory Disease Activity in Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Inhibitors.
Inciarte-Mundo J; Victoria Hernández M; Ruiz-Esquide V; Raquel Cabrera-Villalba S; Ramirez J; Cuervo A; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Care Res (Hoboken); 2016 Jul; 68(7):899-906. PubMed ID: 26841119
[TBL] [Abstract][Full Text] [Related]
19. Calprotectin (a major leucocyte protein) is strongly and independently correlated with joint inflammation and damage in rheumatoid arthritis.
Hammer HB; Odegard S; Fagerhol MK; Landewé R; van der Heijde D; Uhlig T; Mowinckel P; Kvien TK
Ann Rheum Dis; 2007 Aug; 66(8):1093-7. PubMed ID: 17234650
[TBL] [Abstract][Full Text] [Related]
20. Major reduction of ultrasound-detected synovitis during subcutaneous tocilizumab treatment: results from a multicentre 24 week study of patients with rheumatoid arthritis.
Hammer HB; Hansen I; Järvinen P; Leirisalo-Repo M; Ziegelasch M; Agular B; Terslev L
Scand J Rheumatol; 2021 Jul; 50(4):262-270. PubMed ID: 33464147
[No Abstract] [Full Text] [Related]
[Next] [New Search]
